AKUMS

Akums Drugs and Pharmaceuticals Limited

Multi-segment pharmaceutical manufacturer offering CDMO, API and formulations

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

akums.in(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹731.45
Market cap
11,513 Cr
Stock P/E
38.4
P/B
3.38
ROE (FY26)
7.7%
ROCE (FY26)
14.0%
Operating margin (FY26)
8.4%
Debt / equity (FY26)
0.02
OCF / EBITDA (FY26)
226.3%
OCF / EBITDA (3Y)
193.3%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Akums (Akums Drugs and Pharmaceuticals) makes medicines under contract for other pharma companies, including large Indian firms and multinationals, and also sells its own branded medicines, active pharmaceutical ingredients (APIs) and generics.

Company snapshot

42ndBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-09-30 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 82.8% of revenue

SegmentRevenue shareRevenuePBTAssets
API
7.8%
81 Cr-21 Cr457 Cr
Branded and generic formulations
16.9%
175 Cr17 Cr250 Cr
CDMO
82.8%
855 Cr95 Cr2,717 Cr

Shares add up to 108% because segment revenues are before inter-segment eliminations.

What we see

Positives
  • ✓193% of operating profit came in as cash over the last three years — profits are backed by real cash.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales1,019 Cr1,033 Cr1,010 Cr1,056 Cr1,024 Cr1,018 Cr1,160 Cr1,158 Cr1,167 Cr
Operating expenses (approx.)891 Cr912 Cr889 Cr962 Cr895 Cr923 Cr1,013 Cr1,006 Cr992 Cr
EBITDA128 Cr121 Cr121 Cr94 Cr129 Cr94 Cr147 Cr152 Cr175 Cr
OPM %12.6%11.7%12.0%8.9%12.6%9.3%12.7%13.1%15.0%
Other income7 Cr13 Cr15 Cr18 Cr27 Cr32 Cr34 Cr35 Cr30 Cr
Interest13 Cr12 Cr5 Cr5 Cr23 Cr23 Cr24 Cr24 Cr25 Cr
Depreciation34 Cr35 Cr45 Cr40 Cr37 Cr38 Cr40 Cr40 Cr41 Cr
Profit before tax87 Cr92 Cr91 Cr75 Cr96 Cr66 Cr100 Cr121 Cr139 Cr
Tax %30.0%27.2%27.2%-99.1%32.4%35.0%32.0%32.9%27.5%
Net profit61 Cr67 Cr66 Cr150 Cr65 Cr43 Cr68 Cr81 Cr101 Cr
EPS (₹)₹4.21₹4.37₹4.26₹9.64₹4.15₹2.66₹4.33₹5.53₹6.53

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,672 Cr3,655 Cr4,178 Cr4,118 Cr4,359 CrSign in free for the trailing twelve months
Operating expenses (approx.)3,764 Cr3,317 Cr4,055 Cr3,654 Cr3,837 CrSign in free for the trailing twelve months
EBITDA-92 Cr338 Cr123 Cr464 Cr522 CrSign in free for the trailing twelve months
OPM %-2.5%9.2%2.9%11.3%12.0%Sign in free for the trailing twelve months
Other income23 Cr46 Cr34 Cr52 Cr129 CrSign in free for the trailing twelve months
Interest17 Cr46 Cr51 Cr35 Cr94 CrSign in free for the trailing twelve months
Depreciation95 Cr113 Cr126 Cr153 Cr155 CrSign in free for the trailing twelve months
Profit before tax-193 Cr150 Cr-45 Cr345 Cr382 CrSign in free for the trailing twelve months
Tax %-29.9%34.9%101.7%0.4%32.9%Sign in free for the trailing twelve months
Net profit-251 Cr98 Cr0.79 Cr344 Cr256 CrSign in free for the trailing twelve months
EPS (₹)₹-17.65₹6.63₹-0.28₹22.60₹16.67Sign in free for the trailing twelve months
Dividend payout %———0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital14 Cr29 Cr29 Cr31 Cr31 Cr
Reserves608 Cr689 Cr681 Cr3,016 Cr3,283 Cr
Borrowings358 Cr537 Cr492 Cr14 Cr73 Cr
Other liabilities2,086 Cr2,006 Cr2,304 Cr1,036 Cr2,043 Cr
Total liabilities3,069 Cr3,267 Cr3,516 Cr4,113 Cr5,447 Cr
Fixed assets (net)932 Cr963 Cr1,065 Cr1,390 Cr1,448 Cr
CWIP31 Cr103 Cr195 Cr160 Cr177 Cr
Investments0.39 Cr0.14 Cr0.14 Cr0.14 Cr0.14 Cr
Inventories722 Cr730 Cr630 Cr681 Cr756 Cr
Trade receivables884 Cr845 Cr834 Cr770 Cr797 Cr
Cash & bank55 Cr52 Cr111 Cr101 Cr386 Cr
Other assets444 Cr574 Cr681 Cr1,011 Cr1,884 Cr
Total assets3,069 Cr3,267 Cr3,516 Cr4,113 Cr5,447 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity32 Cr177 Cr498 Cr465 Cr1,181 Cr
Cash from investing-235 Cr-305 Cr-330 Cr-548 Cr-930 Cr
Cash from financing236 Cr125 Cr-108 Cr73 Cr34 Cr
Net cash flow33 Cr-4 Cr60 Cr-10 Cr285 Cr
Free cash flow (OCF − Capex)-226 Cr-152 Cr187 Cr193 Cr951 Cr

Ratios

MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %-18.0%15.6%0.4%12.3%14.0%
ROE %-40.4%13.1%-0.6%11.0%7.7%
Debtor days8884736867
Inventory days129131101110120
Days payable1051028510495
Cash conversion cycle111113897491
OCF / EBITDA %—52.3%n.m.100.2%226.3%
OCF / EBITDA % (3 years)——191.4%123.2%193.3%
Debt / equity0.580.750.690.00450.02
Current ratio1.461.481.602.553.25
Net debt / EBITDA—1.443.09-0.19-0.60